IDEAL AND HTA
(AND REIMBURSEMENT)

IDEAL 2017 CONFERENCE

Sean Tunis, MD, MSc

5 May 2017

CMTP

CENTER FOR MEDICAL TECHNOLOGY POLICY

SESSION OBJECTIVE

- To explore how the IDEAL framework could inform HTA methods for assessing clinical studies of implanted medical devices

CMTP

SESSION OUTLINE

Presentations:

- Art Sedrakyan – IDEAL-D
- Tammy Clifford – CADTH / MedTechHTA
- Bruce Gingles – Cook / ISPOR
- Bruce Campbell – MHRA / NICE

Reflections:

- Louis Jacques – ADVI / CMS
- Suzanne Belinson – BCBSA
- Perry Bridger – Edwards Life Sciences
- Danica Marinac-Dabic – FDA/CDRH

"ADEQUATE EVIDENCE" – IN PRACTICE

- How much evidence does a typical payer need in order to be persuaded to cover a clinical intervention?

  Just a little bit more than you currently have.

CMTP

Ladder of Evidential Strength

Higher   **STRENGTH OF**   **Lower**
EVIDENCE

Meta-analysis of individual patient data
Large, multi-center RCTs
Meta-analysis of grouped data
Smaller, single site RCTs
Prospective cohort studies
retrospective cohort

Poorly controlled)
studies (hx control

(Steve Goodman)

Uncontrolled studies
(case-series or reports)